NCT07441499 Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma
| NCT ID | NCT07441499 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Medical University Second Hospital |
| Condition | Urothelial Carcinoma (UC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-03 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2026-03 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Application of Multi-Component Liquid Biopsy (ctDNA, utDNA, Exosomes, and Protein Biomarkers in Blood and Urine) for Auxiliary Diagnosis, Therapeutic Response Evaluation, and Recurrence Monitoring in Urothelial Carcinoma
Eligibility Criteria
Inclusion Criteria: * Suspected or histologically confirmed urothelial carcinoma Exclusion Criteria: * History of or concurrent active malignancy other than urothelial carcinoma
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07441499 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Urothelial Carcinoma (UC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07441499 currently recruiting?
Yes, NCT07441499 is actively recruiting participants. Contact the research team at huhailong@tmu.edu.cn for enrollment information.
Where is the NCT07441499 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT07441499 clinical trial?
NCT07441499 is sponsored by Tianjin Medical University Second Hospital. The trial plans to enroll 300 participants.